Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study
2006-006131-53Phase 3Completed
- Sponsor
- Society for Clinical Research Sites
- Start
- Jan 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in branch retinal vein occlusion (BRVO) (3 arms), sponsored by Society for Clinical Research Sites. Primary endpoint: Change in best spectacle-corrected visual acuity at 6 months. Started Jan 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on 2006-006131-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006131-53.